Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Radient Technologies Inc. Interim / Quarterly Report 2023

Nov 29, 2022

47217_rns_2022-11-29_32ed8f88-f739-4d6d-bc8c-19fa54283aa9.pdf

Interim / Quarterly Report

Open in viewer

Opens in your device viewer

==> picture [204 x 38] intentionally omitted <==

Radient Technologies Inc.

Interim Condensed Consolidated Financial Statements

Three and six months ended September 30, 2022 and 2021 (Unaudited)

Contents

Page
Interim condensed consolidated statements of financial position 4
Interim condensed consolidated statements of operations and comprehensive loss 5
Interim condensed consolidated statements of cash flows 6
Interim condensed consolidated statements of changes in equity 7
Notes to the interim condensed consolidated financial statements 8 - 18

NOTICE OF NO AUDITOR REVIEW OF CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

In accordance with National Instrument 51-102, Part 4, subsection 4.3(3)(a), if an auditor has not performed a review of the condensed consolidated interim financial statements, they must be accompanied by a notice indicating that an auditor has not reviewed the financial statements.

The accompanying unaudited condensed consolidated interim financial statements of the Company have been prepared by and are the responsibility of the Company’s management.

The Company's independent auditor has not performed a review of these financial statements in accordance with the standards established by the Canadian Institute of Chartered Accountants for a review of condensed interim financial statements by an entity's auditor.

==> picture [44 x 8] intentionally omitted <==

1

Radient Technologies Inc.

Interim condensed consolidated statements of financial position

As at September 30,
2022
March 31,
2022
Assets
Current assets
Cash
Lease receivable
Accounts receivable
Prepaids and deposits
Inventories
209,547
$
31,878
$ -
21,008
996,580
117,376
529,704
306,817
2,191,957
2,121,536
3,927,788
2,598,615
Non-current assets
Long-term prepaid and deposits
Lease assets
Plant and equipment
Intangible assets
147,651
147,651
241,136
380,434
21,510,685
22,251,567
2,268,144
2,356,274
24,167,616
25,135,926
Total assets
Liabilities
Current liabilities
Accounts payable and accrued liabilities
Short-term borrowings (Note 5)
Facility construction liabilities
Current portion of long-term debt (Note 6)
Lease liabilities
28,095,404
$
27,734,541
$
22,007,062
$
18,192,063
$ 1,280,000
1,245,000
6,139,757
6,015,277
10,759,774
10,809,814
883,915
1,437,349
41,070,508
37,699,503
Non-current liabilities
Lease liabilities
686,940
160,817
686,940
160,817
41,757,448
37,860,320
Shareholders' deficit
Common shares (Note 7)
Contributed surplus
Deficit
132,141,208
131,900,808
10,220,842
12,073,403
(156,024,094)
(154,099,990)
(13,662,044)
(10,125,779)
Total liabilities and shareholders' deficit 28,095,404
$
27,734,541
$

See accompanying notes to the interim condensed consolidated financial statements

Approved by the Board of Directors:

Director (signed by) "Steven Splinter" Director (signed by) "Jocelyne Lafreniere"

==> picture [44 x 8] intentionally omitted <==

2

Radient Technologies Inc.

Interim condensed consolidated statements of operations and comprehensive loss

2022
2021
2022
2021
Three months ended September 30,
Six months ended September 30,
Revenues
Manufactured products
Manufacturingservices
1,351,082
$
1,097,147
$ 1,920,496
$
1,829,547
$ -
-
-
16,822
1,351,082
1,097,147
1,920,496
1,846,369
Cost of sales
Manufacturedproducts
1,418,055
874,118
1,981,312
1,557,285
1,418,055
874,118
1,981,312
1,557,285
(66,973)
223,029
(60,816)
289,084
Expenses
General and administrative
Financing fees
Depreciation and amortization
Production plant
Engineering
Process development
Research and development
Quality control and assurance
Business development
Corporate development
931,328
582,877
1,329,529
1,125,392
554,589
342,921
1,106,772
766,422
453,693
310,474
907,304
762,248
180,079
216,246
366,692
623,949
-
2,930
1,097
16,545
1,434
145,106
3,741
207,242
3,932
54,715
37,480
114,494
52,850
6,658
83,976
57,429
73,073
53,521

150,655
106,218
-
-

-
5,591
2,250,978
1,715,448
3,987,246
3,785,530
Loss before other expenses (2,317,951)
(1,492,419)
(4,048,062)
(3,496,446)
Other income (expenses)
Share-based payments (Note 7)
Gain on equity settled payables
(Loss) gain on modification of long-term debt (Note 6)
Gain (loss) on disposal of property and equipment
Foreign exchange gain (loss)
Interest and other income
(2,473)
(17,013)
(7,040)
(18,424)
-
36,139
-
36,139
-
(129,935)
248,412
(129,935)
-
67,678
-
(17,594)
1,756
(83,569)
(14,804)
22,429
(15,129)
(19,099)
(25,011)
(28,383)
(15,846)
(145,799)
201,557
(135,768)
Net loss and comprehensive loss
Basic and diluted loss per common share
Weighted average number of common shares outstanding
Basic and diluted
(2,333,797)
$
(1,638,218)
$ (3,846,505)
$
(3,632,214)
$
-
$
-
$ (0.01)
$
(0.01)
$
539,378,891
432,637,825
532,296,853
432,592,263

See accompanying notes to the interim condensed consolidated financial statements

==> picture [44 x 8] intentionally omitted <==

3

Radient Technologies Inc. Interim condensed consolidated statements of cash flows

Radient Technologies Inc.
Interim condensed consolidated statements
of cash flows
For the six months ended September 30, 2022
2021
Operating Activities
Net loss
Adjustments for:
Interest expense and pay-out penalties
Depreciation and amortization
Share-based payments (Note 7)
Gain on modification of long-term debt (Note 6)
Loss on disposal of plant and equipment
Accretion of loss on modification of long-term debt(Note 6)
(3,846,505)
$
(3,632,214)
$ 25,011
762,248
907,304
-
7,040
18,424
(248,412)
129,935
-
17,594
-
(248,764)
Change in non-cash operatingworkingcapital(Note 4) (3,155,562)
(2,988,916)
3,052,626
2,259,087
Cash used in operating activities (102,936)
(729,829)
Financing Activities
Proceeds from private placement (Note 7)
Share issuance costs (Note 7)
Repayment of long-term debt (Note 6)
Shares for service (Note 7)
Shares for debt (Note 7)
Promissory note repayment (Note 5)
Promissorynote received(Note 5)
360,000
-
(56,800)
-
(57,595)
(23,062)
-
12,000
-
222,827
-
-
35,000
545,033
Cashprovided by financing activities 280,605
756,798
Investing Activities
Purchase of plant and equipment
Proceeds on disposal ofplant and equipment
-
(186,718)
-
(9,746)
Cash used in investing activities -
(196,464)
Net increase / (decrease) in cash
Cash,beginningofperiod
177,669
(169,495)
31,878
485,544
Cash, end of the period 209,547
$
316,049
$

Non-cash transactions (Note 4)

See accompanying notes to the interim condensed consolidated financial statements

==> picture [44 x 8] intentionally omitted <==

4

Radient Technologies Inc. Interim condensed consolidated statements of changes in deficit

Common Shares
Contributed
Surplus
Deficit
Shareholders’
Deficit
Balance March 31, 2021
Share-based payments
Shares issued for services
Shares issued for debt
Net loss
127,127,480
$ 17,020,655
$ (146,678,008)
$ (2,529,873)
$ -
18,424
-
18,424
12,000
-
-
12,000
222,827
-
-
222,827
-
-
(3,632,214)
(3,632,214)
Balance September 30, 2021 127,362,307
$ 17,039,079
$ (150,310,222)
$ (5,908,836)
$
Common Shares
(Note 7)
Contributed
Surplus (Note 7)
Deficit
Deficit
Balance March 31, 2022
Private placement
Share-based payments
Option and warrant expiry
Netloss
131,900,808
$
12,073,403
$
(154,099,990)
$
(10,125,779)
$
240,400
62,800
-
303,200
-
7,040
-
7,040
-
(1,922,401)
1,922,401
-
-
-
(3,846,505)
(3,846,505)
Balance September 30, 2022 132,141,208
$
10,220,842
$
(156,024,094)
$
(13,662,044)
$

See accompanying notes to the interim condensed consolidated financial statements

==> picture [44 x 8] intentionally omitted <==

5

Radient Technologies Inc. Notes to the Interim Condensed Consolidated Financial Statements September 30, 2022

1. Nature of operations and going concern

Radient Technologies Inc. was incorporated on June 12, 2001. The principal activities of Radient Technologies Inc. and its subsidiaries, (collectively, the “Company”) are research, development and commercialization of an efficient and environmentally responsible technology for the extraction, isolation and purification of soluble products from a wide range of materials using microwave technology and a customized hydrocarbon extraction platform. The Company is currently focused on the formulation, manufacturing and launching of unique value-added cannabis products. The ordinary shares are listed on the TSXV under the symbol “RTI” and on the OTC Pink, operated by OTC Markets Group under the ticker symbol “RDDTF”. The address of the Company’s head office is 4036 101 St NW, Edmonton, Alberta T6E 0A4 and its registered office is located at 2900 – 550 Burrard Street, Vancouver, British Columbia V6C 0A3.

These interim condensed consolidated financial statements were prepared on a going concern basis, which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of operations as they become due. The Company has a history of significant operating losses and expects to incur further losses in the development of its business. As such, the Company’s status as a going concern is contingent on its ability to increase cash flows or to raise further funds through the issuance of equity or debt. If unsuccessful, the Company will not be able to continue as a going concern.

The Company has incurred significant losses to date. The net loss for the three and six months ended September 30, 2022 totaled $2,333,797 and $3,846,505, respectively (2021 – $1,638,218 and $3,632,214, respectively) and as at September 30, 2022 the Company had a deficit of $156,024,094 (March 31, 2022 - $154,099,990).

In addition, at September 30, 2022, the Company’s current liabilities exceeded its current assets by $37,142,720 (March 31, 2022 – $35,100,888). At September 30, 2022, the Company was in arrears with certain trade creditors, rent, wages, long-term debt, and lease liabilities. Certain of the Company’s trade creditors are pursuing legal recourse for the amounts outstanding. The Company has been able thus far to negotiate settlements with the trade creditors on a case-by-case basis. On May 16, 2022, the Company received a demand letter from the CRA requesting payment of all outstanding excise tax owing. The Company was permitted to renew their cannabis license for an additional six months, from July 6, 2022 to January 5, 2023. On August 26, 2022, the Company received a demand notice from a creditor for payment of their loan. These balances and the changes year over year indicate that there are material uncertainties that may cast significant doubt about the Company’s ability to continue as a going concern.

Management has been able to finance operations through debt and equity financings and will continue, as appropriate, to seek financing from these and other sources; however, there are no assurances that any such financings can be obtained on favourable terms, if at all. There can be no assurance that the steps management is taking will be successful.

The financial statements for the years presented do not include any adjustments to the amounts and classification of assets and liabilities that might be necessary should the Company be unable to continue in business as a going concern and that such adjustments could be material.

During the 2020, 2021 and 2022 calendar years, there continued to be a global pandemic outbreak of COVID-19. The actual and threatened spread of the virus globally has had a material adverse effect on the global economy and, specifically, the regional economies in which the Company operates. The pandemic could continue to have a negative impact on the stock market, including trading prices of the Company’s shares and its ability to raise new capital. These factors, among others, could have a significant impact on the Company’s operations. Management has given consideration to the impact of COVID-19 on the Company and has concluded that the interim condensed consolidated financial statements appropriately reflect and disclose management’s best estimate and uncertainty regarding the impact of COVID-19 on the Company’s future operations and financial results.

==> picture [44 x 8] intentionally omitted <==

6

Radient Technologies Inc. Notes to the Interim Condensed Consolidated Financial Statements September 30, 2022

These interim condensed consolidated financial statements, including comparatives, were authorized for issue by the Board of Directors of the Company on November 29, 2022.

2. Basis of presentation

a) Statement of compliance

These interim condensed consolidated financial statements have been prepared in accordance with International Accounting Standard 34: “Interim Financial Reporting”, as issued by the International Accounting Standards Board (IASB). The same accounting policies were followed in the preparation of these interim condensed consolidated financial statements as were followed in the preparation of the annual consolidated financial statements for the year ended March 31, 2022. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Company’s financial position and performance since the last annual financial statements.

b) Basis of consolidation

The interim condensed consolidated financial statements of the Company include the financial statements of Radient Technologies Inc. and its wholly-owned subsidiaries Radient Technologies (Cannabis) Inc. (“RTC”), Radient Technologies Innovations Inc. (“RII”), and 1631807 Alberta Ltd.

Subsidiaries are fully consolidated from the date of acquisition, being the date on which the Company obtains control, and continue to be consolidated until the date that such control ceases. On acquisition, the assets, liabilities and contingent liabilities of a subsidiary are measured at their fair values. If accounted for as a business combination, any excess of the cost over the fair values of the identifiable net assets acquired is recognized as goodwill. If accounted for as a purchase of assets, any excess of the cost over fair value of the identifiable net assets is allocated to the assets purchased.

The financial statements of the subsidiaries are prepared for the same reporting period as the parent company using consistent accounting policies. All transactions and balances between the Company and its subsidiaries are eliminated upon consolidation.

c) Basis of measurement

The interim condensed consolidated financial statements have been prepared under the historical cost convention, unless otherwise indicated.

d) Functional and presentation currency

Amounts presented in these interim condensed consolidated financial statements and the notes hereto are in Canadian dollars, the parent Company’s functional currency, unless otherwise stated.

3. Summary of significant accounting policies

Significant estimates

The preparation of interim condensed consolidated financial statements requires management to make critical judgments, estimates and assumptions that affect the reported amounts of certain assets and liabilities and disclosure of contingent assets and liabilities at the date of the interim condensed consolidated financial statements and the reported amounts of revenues and expenses recorded during the reporting period. In making estimates and judgments, management relies on external information and observable conditions where possible, supplemented by internal analysis as required. Actual results may differ from those estimates. Estimates and assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

==> picture [44 x 8] intentionally omitted <==

7

Radient Technologies Inc. Notes to the Interim Condensed Consolidated Financial Statements September 30, 2022

New accounting standards issued but not yet effective

Certain new accounting standards and interpretations have been published that are not mandatory for the current period and have not been early adopted. These standards are not expected to have a material effect on the Company in the current of future reporting periods.

4. Change in non-cash operating working capital

4. Change in non-cash operating working capital
September 30,
2022
September 30,
2021
Accounts receivable
Prepaids and deposits
Inventories
Facility construction liabilities
Accounts payable and accrued liabilities
Net change in non-cash operating working capital
$ (858,196) $ (504,225)
(222,887) (125,469)
(70,421)
55,642
124,480
-
4,079,6502,833,139
$ 3,052,626 $2,259,087

5. Short-term borrowings

On January 31, 2020, the Company entered into a loan agreement with Akaura Holdings Inc. (“Akaura”, a related party) to assist the Company with working capital requirements. The amount funded under the loan agreement was $2,500,000 and beared interest at 21.0% per annum. $200,000 was held back by the lender and was recorded as long-term restricted cash. Interest was accrued monthly with the principal balance due on February 28, 2020. With the loan unpaid at February 28, 2020, an additional penalty of $60,000 was due immediately with a further per diem penalty of $2,000 per day accruing from February 15, 2020 until all principal, interest and penalties were repaid in full.

At February 2, 2021, the Company owed the original principal of $2,500,000 less the $200,000 holdback, and $981,664 of accrued interest and default fees related to the loan. The Company renegotiated the terms of the loan with Akaura in February 2021. As a result of the renegotiation, the Company issued 20,952,381 shares of the Company to Akaura to settle $2,200,000 of the Company’s outstanding debt with Akaura. Akaura extended $1,000,000 of the outstanding liability under a new agreement with the Company and forgave $219,937 of the Company’s existing debt. The Company reimbursed Akaura for legal and financing fees of $138,273 relating to the renegotiation.

The new loan agreement allowed an interest free period on the loan until June 1, 2021, at which time the $1,000,000 was to be paid in full. If the loan was not repaid on June 1, 2021, interest in the amount of 3% per month, retroactive to March 2021 would be charged until payment was received in full.

The Company concluded that the terms of the new agreement were substantially modified from the terms of the original agreement and as such, the renegotiation of the loan was treated as an extinguishment of the original debt and the modified loan was recorded as new debt.

The loan is secured through a mortgage on land and building as well as a general security agreement between Akaura Holdings Inc. and two of the Company’s subsidiaries. Akaura retained all rights and security pertaining to the second mortgage under the new debt agreement.

This loan was not repaid on June 1, 2021 and as such, an interest expense of $90,000 and $180,000 was recorded in the statement of operations for the three and six months ended September 30, 2022, respectively, (September 30, 2021 - $90,000 and $210,000, respectively), and no financing fees were presented under financing fees for the three and six months ended September 30, 2022 (2021 - $nil and $nil, respectively).

==> picture [44 x 8] intentionally omitted <==

8

Radient Technologies Inc. Notes to the Interim Condensed Consolidated Financial Statements September 30, 2022

The Company entered into $545,033 in promissory notes during the year ended March 31, 2022 and repaid $300,033 of the promissory notes. The promissory notes matured six months from the date of the promissory note issuance. The outstanding promissory notes matured on February 10, 2022, February 21, 2022 and March 20, 2022. The remaining promissory notes were not repaid as of September 30, 2022.

The Company entered into a $35,000 promissory note during the six months ended September 30, 2022. The promissory note matures six months from the date of the promissory note issuance. The promissory note matures on December 22, 2022.

6. Long-term debt

September 30, March 31,
2022 2022
Loan payable bearing interest at 5.80% with monthly payments of $9,327
maturing October 1, 2021 (Note 11(a))
$ 89,468 $ 141,990
Loan payable bearing interest at 4.55% with monthly payments of $2,586
maturing March 1, 2023 (Note 11(a))
83,964 81,482
Loan payable bearing interest at Bank of Canada policy interest rate plus
3% with variable payments maturing June 1, 2025 (Note 11(b))
657,266 657,266
Mortgage payable bearing interest at the greater of 9.99% or Bank of Nova
Scotia prime rate plus 7.54% per annum with monthly interest only
payments required and principal maturing on November 1, 2022 (Note
9,929,076 9,929,076
11(c))
10,759,774 10,809,814
Currentportion (10,759,774) (10,809,814)
$ - $-

For the three and six months ended September 30, 2022, total interest expense related to long-term debt was $280,865 and $562,682 respectively ($380,036 and $711,887 for the three and six months ended September 30, 2021, respectively)

(a) Agriculture Financial Services Corporation (“AFSC”) loans payable

As at September 30, 2022, the Company was 31 months in arrears on these loans. Arrears interest and penalties owing are $5,694 (March 31, 2022 - $10,833) and are included in accounts payable and accrued liabilities. AFSC had provided the Company until February 15, 2021 to cure the payments in arrears as well as the additional arrears interest and penalties. The Company did not pay these arrears to the AFSC by February 15, 2021. On October 27, 2021, the Company received a notice of intention to enforce security in relation to the AFSC loans. Attempts to negotiate a forbearance agreement with AFSC have not been successful and AFSC has indicated its intention to collect Company assets to satisfy the liability. The Company has been working with AFSC to secure an orderly sale of non-core assets to satisfy its obligation to AFSC, however, in June 2022, AFSC indicated that they would no longer accept partial payments of the loan and were in the process of securing an auctioneer to assist with the sale of select assets of the Company.

The Company repaid $57,595 of the AFSC loan during the six months ended September 30, 2022.

==> picture [44 x 8] intentionally omitted <==

9

Radient Technologies Inc. Notes to the Interim Condensed Consolidated Financial Statements September 30, 2022

(b) Ministry of Agriculture and Agri-Foods Canada (“AAFC”) loan payable

As at September 30, 2022, the Company was 28 months in arrears on the AAFC loan with arrears interest owing of $64,093 (March 31, 2022 - $51,576) which is included in accounts payable and accrued liabilities.

(c) Moskowitz Capital Mortgage Fund II Inc. (“Moskowitz”)

On April 29, 2020, the Company amended the mortgage with Moskowitz increasing the interest rate to the greater of 12.5% or Bank of Nova Scotia prime rate plus 10.05% per annum revised from the greater of 8.5% or Bank of Nova Scotia prime rate plus 5.05% per annum. As the terms of the amendment to the mortgage were not substantially different from the terms of the previously existing mortgage, the amendment was determined to be a modification of debt. As a result, a loss on modification of long-term debt with corresponding increase to the value of the debt totalling $477,810 was recognized. This adjustment is amortized back to the debt over the remaining term of the mortgage. Deferred financing charges of $85,000 related to the loan amendment fee were recorded and are amortized over the remaining term of the mortgage.

On October 2, 2020, Moskowitz agreed to defer arrears payments owing related to interest and non-interest bearing amendment fees payable to December 31, 2020 for a fee of $90,000.

On January 15, 2021, the deferral agreement was extended to February 28, 2021 for an additional fee of $50,000 and 550,000 shares of Radient. The shares were issued to Moskowitz on February 1, 2021.

On May 3, 2021, the Company amended the mortgage with Moskowitz increasing the interest rate to the greater of 15% or Bank of Nova Scotia prime rate plus 12.55% per annum revised from the greater of 12.5% or Bank of Nova Scotia prime rate plus 10.05% per annum. As the terms of the amendment to the mortgage were not substantially different from the terms of the previously existing mortgage, the amendment was determined to be a modification of debt. As a result, a loss on modification of long-term debt with corresponding increase to the value of the debt totalling $129,935 was recognized. This adjustment is amortized back to the debt over the remaining term of the mortgage. This amendment also included bonus standby interest of $35,000, to be paid in shares of the Company.

On November 1, 2021, the Company’s loan with Moskowitz matured. The Company negotiated a loan renewal with Moskowitz. Under the renewal, outstanding interest of $1,429,076 was added to the outstanding principal of $8,500,000 for total principal of $9,929,076, with an interest rate of the greater of 9.99% or Bank of Nova Scotia prime rate plus 7.54% per annum, and a maturity date of November 1, 2022. The renewal agreement included a renewal fee of $99,929, payable in three installments of $33,309 on February 1, 2022, March 1, 2022 and April 1, 2022. Further, the Company will pay bonus interest of 10,000,000 common share purchase warrants, entitling the mortgage holder to purchase one common share of the Company for each warrant. at a price of $0.085, expiring December 1, 2023 as part of the renewal agreement. The value of the warrants has been estimated to be $200,148 using the Black-Scholes model with the following assumptions: share price of $0.05, volatility of 99.93% based on the Company’s historical volatility, risk-free rate of $1.35%, 0% dividend yield and time to maturity of 1 years, and has been included in accounts payable and accrued liabilities as at June 30, 2022.

The mortgage is secured by the Company’s production facility and the adjacent lands.

On April 4, 2022, the Company amended the mortgage with Moskowitz adjusting the exercise period of the 10 million common share purchase warrants to one year, down from a two-year exercise period under the original agreement. The value of the warrants has been estimated to be $200,148 using the Black-Scholes model with the following assumptions: share price of $0.05, volatility of 99.93% based on the Company’s historical volatility, risk-free rate of $1.35%, 0% dividend yield and time to maturity of 1 years, and has been included in accounts payable and accrued liabilities as at June 30, 2022. As a result of this change, the Company recorded a gain on modification of the loan of $248,412 on the consolidated statement of operations.

==> picture [44 x 8] intentionally omitted <==

10

Radient Technologies Inc. Notes to the Interim Condensed Consolidated Financial Statements September 30, 2022

On August 26, 2022, Moskowitz issued a demand notice to the Company for payment of this loan, plus accrued costs and interest pursuant to the terms of the loan. The Company is evaluating its options with respect to this demand notice.

7. Share capital

a) Common shares

i) Authorized

Unlimited number of common shares without par value

ii) Issued and outstanding common shares

ii) Issued and outstanding common shares
Shares
Amount
Balance, March 31, 2021
Shares issued for debt
Shares issued for services
Private placement
Tunaaaa acquisition
432,546,200 $ 127,127,480
7,179,974
417,770
261,133
21,000
20,880,714
1,029,558
70,000,000
3,305,000
Balance, March 31, 2022
Private placement
530,868,021 $ 131,900,808
9,000,000
240,400
Balance, September 30, 2022 539,868,021 $
132,141,208

On July 6, 2022, the Company closed its first tranche of a private placement. Under the first tranche, the Company issued 9 units at a price of $40,000 per unit for gross proceeds of $360,000. Each unit consists of 1,000,000 common shares of the Company and 500,000 common share purchase warrants, with each warrant entitling the holder to purchase one common share of the Company at $0.07 per share for 36 months after closing. The Company paid finder’s fees of $28,800 in cash and will issue 0.72 units in relation to the private placement. The 0.72 units to be issued as part of the finder’s fees for this private placement had not been issued as at September 30, 2022 and the corresponding liability has been included in accrued liabilities at September 30, 2022.

b) Finder’s options

As part of the brokered placement on May 26, 2020, the Company also issued finder’s options to certain finders that entitled them to acquire 1,630,275 units at an exercise price of $0.20 for a period of 36 months following the completion of the offering. If exercised, these units would include 1,630,275 common shares and 1,630,275 common share purchase warrants entitling the holder to subscribe for additional common shares at a price of $0.30 per common share for a period of 36 months.

The common share finders’ options were allocated a portion of the gross proceeds based upon their relative fair value at the date of issuance. A total of $384,745 was recorded as share issue costs as of March 31, 2021 ($202,154 allocated to common shares and $182,591 to common share purchase warrants). The Black-Scholes option pricing valuation model was utilized to value the finder’s options.

==> picture [44 x 8] intentionally omitted <==

11

Radient Technologies Inc. Notes to the Interim Condensed Consolidated Financial Statements September 30, 2022

A summary of the assumptions used for each component of the finder’s options is set out below:

Common Common
Shares Share
Purchase
Warrants
Finder’s Options
Common share market price $ 0.20 $ 0.30
Risk free interest rate 1.75% 1.75%
Expected dividend yield - -
Estimated common share price volatility 114% 114%
Estimated life in years 3 3

The continuity of the Company’s outstanding finders’ options is as follows:

Six months ended
September 30, 2022
Number of
options
Weighted
average
exercise
price
Year ended
March 31, 2022
Number of
options
Weighted
average
exercise
price
Outstanding, beginning of period
1,630,275
$
0.20

1,630,275
$
0.20
Outstanding, end of period 1,630,275
$
0.20
1,630,275
$
0.20

There were no finders’ options exercised during the six months ended September 30, 2022 and year ended March 31, 2022.

If exercised, the options outstanding at September 30, 2022 of 1,630,275 would include 1,630,275 common shares and 1,630,275 common share purchase warrants.

c) Shares and units issued for debt

During the year ended March 31, 2022, the Company issued common shares of the Company to settle amounts owing to certain third-party creditors as well as some directors and officers. Specific details for the transactions are summarized as follows:


ansactions are summarized as follows:
Share issue date July 28, 2021 January 28, 2022
Issue price per unit / share $ 0.105 $ 0.06
Common shares issued 2.488,306 4,691,667
Debt amount settled $ 261,272 $ 281,500
Gain on settlement of debt (36,139) (70,375)
Cash issuance costs (2,306) (2,408)
Net value allocated to common shares $ 222,827 $ 208,717

During the year ended March 31, 2022, the Company recognized a gain on equity settled payables of $36,139. Shares issued for debt with related parties are recorded at the value of the debt settled with no gain or loss recorded through the consolidated statement of operations.

==> picture [44 x 8] intentionally omitted <==

12

Radient Technologies Inc. Notes to the Interim Condensed Consolidated Financial Statements September 30, 2022

d) Shares for services

There were 261,133 common shares of the Company issued during the year ended March 31, 2022 with a net value allocated to common shares of $21,000 related to the shares for service agreement described above. There were no shares issued for services in the six months ended September 30, 2022.

e) Warrants

The continuity of the Company’s outstanding warrants is as follows:

Six months ended
September 30, 2022
Number of
warrants
Weighted
average
exercise
price
Year ended
March 31, 2022
Number of
warrants
Weighted
average
exercise
price
Outstanding, beginning of period
Warrants issued
Warrants expired

67,988,841
$
0.21
4,500,000
0.07
(3,358,127)
0.25

42,683,781
$ 0.29
35,880,714
0.12
(10,575,654)
0.25
Outstanding, end of period 69,130,714
$
0.21
67,988,841
$ 0.21

20,880,714 warrants issued during the year ended March 31, 2022 relate to the December 31, 2021 placement. The warrants have an exercise price of $0.10 and are exercisable any time prior to June 30, 2023.

15,000,000 warrants issued during the year ended March 31, 2022 relate to the Tunaaaa Xtracts Inc. acquisition. These warrants have an exercise price of $0.15 and are exercisable any time prior to January 28, 2024.

4,500,000 warrants issued during the six months ended September 30, 2022 relate to the July 6, 2022 placement. The warrants have an exercise price of $0.07 and are exercisable any time prior to 36 months after issue.

The following table summarizes information about warrants outstanding as at September 30, 2022 and March 31, 2022.

September 30, 2022
Exercise
price
Number of
warrants
Remaining
contractual
life (years)
-
-
-
0.30
28,750,000
1.4
0.10
20,884,714
1.5
0.15
15,000,000
1.8
0.07
4,500,000
2.8
$ 0.21
69,130,714
1.0
March 31, 2022
Exercise Price
Number of
warrants
Remaining
contractual
life (years)
0.30
3,358,127
0.2
0.30
28,750,000
1.4
0.10
20,884,714
1.5
0.15
15,000,000
1.8
-
-
-
$ 0.21
67,988,841
1.3

==> picture [44 x 8] intentionally omitted <==

13

Radient Technologies Inc. Notes to the Interim Condensed Consolidated Financial Statements September 30, 2022

f) Stock option plan

The Company’s stock option plan (the “Stock Option Plan”) provides that the Board of Directors of the Company may from time to time, in its discretion, grant to directors, officers, employees and consultants of the Company non-transferable options to purchase common shares, provided that the number of common shares reserved for issuance under the Stock Option Plan shall not exceed ten percent (10%) of the issued and outstanding common shares exercisable for the period of up to ten (10) years.

In addition, the number of common shares reserved for issuance to any one person shall not exceed five percent (5%) of the issued and outstanding common shares and the number of common shares reserved for issuance to any one consultant will not exceed two percent (2%) of the issued and outstanding common shares. The Board of Directors determines the price per common share and the number of common shares which may be allocated to each director, officer, employee and consultant and all other terms and conditions of the option, subject to the rules of the TSXV. Options have been issued with vesting periods of immediate to 4 years with terms between 2 and 10 years.

The continuity of the Company’s outstanding and exercisable stock options is as follows:

Six months ended
September 30, 2022
Number of
options
Weighted
average
exercise
price
Year ended
March 31, 2022
Number of
options
Weighted
average
exercise
price
Outstanding, beginning of period
Options granted
Options expired
Options forfeited

18,230,772 $
0.58
-
-
(3,967,772)
0.58
-
0.12

29,838,447 $ 0.58
-
-
(10,317,050)
0.58
(1,290,625)
0.12
Outstanding, end of period 14,263,000
$
0.62
18,230,772
$ 0.62
Exercisable, end of period 13,986,360
$
0.64
17,797,062
$ 0.64

The Company issued 2,000,000 options to a director of the Company on February 11, 2021 that will vest based on performance milestones. The milestones for these options had not been defined as at September 30, 2022 and therefore, the options are not considered to be granted.

For stock options granted, the Company records compensation expense using the fair value method. Fair values are determined using the Black-Scholes Option pricing model. Compensation costs are recognized over the vesting period as an increase to share based payments expense and contributed surplus. When stock options are subsequently exercised, the fair-value of such stock options in contributed surplus is credited to share capital. When stock options expire, unexercised or are cancelled, the fair-value of such stock options in contributed surplus is credited to retained earnings.

The estimated volatility is based on the Company’s historic volatility since May 22, 2014.

There were no stock options exercised during the six months ended September 30, 2022 or the year ended March 31, 2022.

==> picture [44 x 8] intentionally omitted <==

14

Radient Technologies Inc.

Notes to the Interim Condensed Consolidated Financial Statements September 30, 2022

The following table summarizes information about stock options outstanding as at September 30, 2022 and March 31, 2022:

September 30, 2022
Remaining
Exercise
Number of
contractual
price
options
life (years)
$ -
-
-
1.82
518,000
0.2
1.20
50,000
0.7
1.82
2,600,000
1.0
0.87
2,225,000
1.2
0.93
20,000
1.7
0.75
300,000
1.7
0.58
150,000
2.1
0.37
250,000
2.4
0.175
250,000
2.7
0.10
750,000
3.0
0.15
7,150,000
3.4
$ 0.58
14,263,000
2.4
March 31, 2022
Remaining
Exercise
Number of
Contractual
price
options
life (years)
$ 0.66
2,267,772
0.0
1.82
518,000
0.7
1.20
50,000
1.2
1.82
2,600,000
1.5
0.87
2,425,000
1.7
0.93
20,000
2.2
0.75
400,000
2.2
0.58
150,000
2.6
0.37
500,000
2.9
0.175
400,000
3.2
0.10
1,000,000
3.5
0.15
7,900,000
3.9
$0.58
18,230,772
2.5

The total share-based payments recognized during the three and six months ended September 30, 2022 of $2,473 and $7,040, respectively ($17,013 and $18,424 for the three and six months ended June 30, 2021, respectively) were recorded as an expense.

8. Commitments and contingencies

The Company has entered into various non-cancellable commitments with contract terms ranging between one and five years as follows:

September 30,
March 31,
2022
2022
Capital expansion projects
Leases not yet commenced
Variable lease payments for lease liabilities
Network services contracts
Purchase and retrofitting of equipment
Maintenance contracts
Direct materials
$
1,340,542
$ 1,340,542
130,500
130,500
978,046
1,183,003
36,342
7,568
89,083
89,083
-
12,567
570,000
570,000
$
3,144,513
$ 3,333,263

==> picture [44 x 8] intentionally omitted <==

15

Radient Technologies Inc. Notes to the Interim Condensed Consolidated Financial Statements September 30, 2022

9. Financing fees

9. Financing fees
Three months ended September 30, Six months ended September 30,
2022 2021 2022 2021
Amortization of financing costs on long-term debt $ -$ (23,526) $ -$ 28,333
Interest on long-term debt 280,865 380,036 562,682 711,887
Interest on lease liabilities 6,674 41,278 13,560 41,278
Interest on short-term borrowings 112,050 109,627 220,530 229,627
Accretion of interest - (167,005) - (248,764)
Other 155,000 2,511 310,000 4,061
$ 554,589 $342,921$ 1,106,772 $766,422

10. Related party transactions

The Company’s related parties are its Board of Directors, and key management personnel (President and Chief Executive Officer, Chief Operating Officer, Chief Financial Officer and Chief Technology Officer), as well as any companies controlled by key management personnel or directors. Transactions conducted with related parties took place in the normal course of operations and are measured at the amount of consideration established and agreed to by the related parties.

Balances and transactions between the Company and its subsidiaries, which are related parties, have been eliminated on consolidation and are not disclosed in this note.

a) Key management personnel and director remuneration

The remuneration of directors and key management personnel follows:

Six months ended September 30, 2022 2021
Compensation $ 126,375$ 147,750
Short-term benefits - 6,465
$ 126,375$ 154,215

Compensation includes key management salaries, consulting fees and director’s fees.

As at September 30, 2022, $897,329 (March 31, 2022 - $821,680) was included in accounts payable and accrued expenses for amounts owing to key management personnel, directors and companies controlled by key management personnel or directors.

b) Loans and cash advances

i) During the six months ended September 30, 2022

A director of the Company advanced $116,110 to the Company. This advance is non-interest bearing, has no fixed repayment terms and is payable on demand.

==> picture [44 x 8] intentionally omitted <==

16

Radient Technologies Inc. Notes to the Interim Condensed Consolidated Financial Statements September 30, 2022

11. Financial instruments

Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulties in meeting its financial obligations.

The Company manages its liquidity risk by forecasting cash flow requirements for its planned development, production and corporate activities and anticipating investing and financing activities. Management and the Board of Directors are actively involved in the review, planning and approval of annual budgets and significant expenditures and commitments. The Company has disclosed (Note 1) that continuation as a going concern is dependent on obtaining sufficient funds to discharge contractual liabilities as well as funding continuing operations.

The Company’s contractual liabilities and obligations are as follows:

< 1 year
1 to 3 years
4 to 5
years
>5
years
Total
Accounts payable and accrued liabilities
Facility construction liabilities
Short-term borrowings
Long-term debt
Lease liabilities
$22,007,062
$ - $ - $ - $22,007,062
6,139,757
- - - 6,139,757
1,280,000
- - - 1,280,000
10,759,774
- - - 10,759,774
883,915 686,940
- - 1,570,855
Balance September 30, 2022
Accounts payable and accrued liabilities
Facility construction liabilities
Short-term borrowings
Long-term debt
Lease liabilities
$41,070,508 $ 686,940
$ - $ - $41,757,448
$18,192,063
$ - $ - $ - $18,192,063
6,015,277
- - - 6,015,277
1,245,000
- - - 1,245,000
10,809,814
- - - 10,809,814
1,437,349 160,817
- - 1,598,166
Balance March 31, 2022 $37,699,503$160,817
$-$-$37,860,320

The contractual liabilities and obligations included in the tables above include both principal and interest cash flows.

12. Subsequent Events

On October 24, 2022, the Company discovered that equipment valued at $1.7M was missing. A police investigation is currently underway.

As of October 26, 2022, Akaura Holdings Inc. ceased to be a related party of the Company.

==> picture [44 x 8] intentionally omitted <==

17